May 17, 2020

China is looking at ways to eradicate bottlenecks in drug development

China
pharmaceutical
Medicine
pharmaceutical
Catherine Sturman
2 min
China pharmaceutical
China has long been furthering its ambitions to become a key player within the pharmaceutical industry. Despite a number of acquisitions and long-term i...

China has long been furthering its ambitions to become a key player within the pharmaceutical industry. Despite a number of acquisitions and long-term investments, traditional bottlenecks remain within the development of drug which are delayed when entering the Chinese drug market.

Compulsory clinical trials of all developed drugs entering China has seen the country approve just over 100 new drugs in the last five years, which has been reported as a third of drugs within developed markets. It can take up to 7-8 years for overseas drugs to therefore enter the Chinese market.

The government is now looking at ways in which to support the growing industry, counteract high medicine costs and support its growing population by overhauling this traditional practice.

Beijing has recently stated that overhauling the ban on data from overseas clinical trials will further support the development of drugs in the country and see the rise of new treatments to support patients, reduce delays in treatment, increase potential revenue and further the country’s opportunities within the pharmaceutical sector amidst growing competition globally.

Related stories

“Overall, China’s support for scientific innovation with drugs and medical devices is lacking, and the quality of products on the market still falls short of top international levels,” China’s draft proposals have said.

“We must therefore speed up the examination and approval of urgently needed drugs and medical devices.”

Shares in Chinese drug makers rose upon the news announcement by over 6%.

Additionally, Bloomberg recently reported that the country will also be working on strengthening its hold on protecting its medical intellectual property to ensure that the changes do not affects its ongoing competitiveness in the market. The government has consequently stated that it will also look at implementing a new system which will connect drug approvals to patent status to further its ambitions in this space.

Share article

Jun 22, 2021

Bachem turns 50 - a timeline

pharma
supplychain
peptides
medication
3 min
As Bachem turns 50, we take a look at the company's history

Bachem, a supplier to pharmaceutical and biotechnology companies worldwide, is celebrating its 50th anniversary this month. We take a look at the Swiss company's history.  

1971 - beginnings

Bachem is founded by entrepreneur Peter Grogg in Liestal, a small town near Basel in Switzerland. Grogg started the firm with just two employees, and with a focus on peptide synthesis - peptides are composed of amino acids that have a variety of functions treating health conditions such as cancer and diabetes. 

1977 - 1981 - early growth

Bachem moves its headquarters to the Swiss town of Bubendorf, with eight employees. In 1978 the company produces peptides for use in medicines for the first time. In 1981 production capacity triples and the workforce grows to 150. 

 1987 - 1996 - worldwide expansion

The company expands into the US with Bachem Bioscience, Inc. in Philadelphia. To strengthen its presence in Europe, Bachem opens sales and marketing centres in Germany in 1988. 

Further sales centres open in France in 1993. By 1995 the company employs 190 people. In 1996 it acquires the second largest manufacturer of peptides in the world and forms Bachem California with a site in Torrance. 

 1998 - 2003 - Bachem goes public

Bachem company goes public and lists shares on the Swiss Stock Exchange. Further acquisitions include Peninsula Laboratories, Inc, based in California, and  Sochinaz SA, a Swiss-based manufacturer of active pharmaceutical ingredients.  By 2001, the company has 500 employees and sales reach 141 million CHF.

In 2003 the organisation is given a new legal holding structure to support its continued growth, which remains in place to this day. 

2007 - 2013 - acquisitions

Bachem acquires a brand by Merck Biosciences for ready-to-use clinical trial materials and related services. 

In 2013, together with GlyTech, Inc. Bachem announces the development of a new amino acid that can help to treat multiple sclerosis, with a world market of more than $4 billion. 

In 2015 it acquires the American Peptide Company (APC), which becomes integrated into Bachem Americas. 

2016 - 2019 - a global leader

In 2016 the group opens a new building dedicated to R&D projects and small series production in Bubendorf. With a total of 1,022 employees, the workforce exceeds the 1,000 mark for the first time in the company’s history. Sales are over the 200 million mark for the first time at 236.5 million CHF.
Bachem expands into Asia with the establishment of a new company in Tokyo called Bachem Japan K.K. 

By 2019 Bachem has a growing oligonucleotide portfolio - these are DNA molecules used in genetic testing, research, and forensics. It is hoped this will become a significant product range in the future. 

2020 - COVID-19

Despite the COVID-19 pandemic, Bachem secures its supply of active ingredients, and even increases it in critical areas. Sales exceed the 400 million Swiss franc mark for the first time, and  272 new employees are hired.  

2021 - a milestone anniversary

Bachem celebrates its 50th anniversary and position as a global leader in the manufacture of peptides. While it  remains headquartered in Bubendorf, the company employs 1,500 people at six locations worldwide. In the next five years there are  plans to continue expanding. 

Commemorating the company's anniversary, Kuno Sommer, Chairman of the Board of Directors, said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values, and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."

Share article